ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...
Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback